With the identification of several Alzheimer disease (AD)-associated genes, genetic testing for AD is possible. However, as for some other-late onset disorders, the ethical and social implications of such tests are considerable. In response to the commercial availability and the likely increased use of AD genetic tests, The Stanford Program in Genomics, Ethics, and Society formed a broad-based working group to examine the pros and cons of testing. Here they present their recommendations.
- L.M. McConnell
- B.A. Koenig
- T.A. Raffin
